Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Doxycline · 1 trial · 1 indication
Description of skin rash (folliculitis, including erythema, papulo-pustules, nodule, and crust) was according to Common Terminology Criteria for Adverse Events (CTCAE) version 3 scale. Medical pictures of the face (front and sides views) systematically, and of any region presenting with skin lesions were obtained. The pictures were reviewed by a centralized committee of evaluation.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Doxycline | DRUG | 100mg po daily |
| erlotinib [Tarceva] | DRUG | 150mg po daily |
Inclusion Criteria: * adult patients, 18-75 years of age; * confirmed non-small cell lung cancer; * failure after first line chemotherapy for advanced disease, and scheduled for second line therapy with Tarceva. Exclusion Criteria: * rash of any etiology at study entry; * history of significant h...
Top 20 of 90 competitors
Doxycline is an investigational small molecule being studied for use in Non-Small Cell Lung Cancer (NSCLC). It is currently in Phase 2 clinical development, with one completed trial that enrolled 147 patients in France. The drug is being developed by Roche Holding AG.
The molecular target and target class for Doxycline have not been disclosed in the available information. As a small molecule, it is being investigated for its potential role in managing Non-Small Cell Lung Cancer, but its specific mechanism of action is not publicly detailed.
Doxycline is being developed by Roche Holding AG, a biopharmaceutical company. Roche is conducting clinical trials to evaluate the drug's safety and efficacy in patients with Non-Small Cell Lung Cancer.
Doxycline is in Phase 2 clinical development. It is an investigational drug, not yet approved by regulatory authorities. One Phase 2 trial has been completed, and the drug remains under evaluation for Non-Small Cell Lung Cancer.
Doxycline has one completed clinical trial, NCT00531934, titled 'A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer.' This Phase 2 study enrolled 147 patients in France and was active-controlled, though it is no longer ongoing.
No, Doxycline is not the same as Tarceva. The completed trial NCT00531934 studied the management of Tarceva-induced rash in Non-Small Cell Lung Cancer patients, indicating Doxycline was evaluated as an adjunct therapy to manage side effects, not as a substitute for Tarceva.